Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCET vs GANCICLOVIR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, though it can interact with other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Acetaminophen is believed to produce analgesia through central action, possibly mediated through inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways, though the exact mechanism is not fully understood.
Ganciclovir is a synthetic guanine nucleoside analog that inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and by incorporating into viral DNA, causing chain termination. It requires initial phosphorylation by viral thymidine kinase (CMV) or protein kinase (HSV).
Management of moderate to moderately severe pain where an opioid analgesic is appropriate,Off-label use: Relief of pain in various conditions including postoperative pain, traumatic pain, and chronic pain
Treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including AIDS patients.,Prevention of CMV disease in transplant recipients at risk.,Treatment of CMV pneumonitis, colitis, esophagitis, and other CMV infections in immunocompromised patients (off-label).,Treatment of herpes simplex virus (HSV) infections resistant to acyclovir (off-label).
1 tablet (325 mg acetaminophen and 5 mg oxycodone) orally every 4 to 6 hours as needed for pain; maximum 12 tablets per day.
Induction: 5 mg/kg IV every 12 hours for 14-21 days. Maintenance: 5 mg/kg IV every 24 hours. Oral: 1000 mg three times daily with food.
The terminal elimination half-life of oxycodone is approximately 3.5-4 hours for immediate-release formulations. For controlled-release formulations, the half-life is similar due to absorption-limited elimination, but the duration of action is extended due to the formulation. In elderly patients or those with hepatic impairment, half-life may be increased up to 2-fold.
Terminal half-life: 2.5-5.0 hours in normal renal function; prolonged to 10-30 hours in renal impairment; requires dose adjustment for Cr Cl <70 m L/min
Oxycodone is extensively metabolized in the liver via cytochrome P450 3A4 (CYP3A4) and CYP2D6 to noroxycodone, oxymorphone, and noroxymorphone. Acetaminophen is primarily metabolized in the liver via conjugation (glucuronidation and sulfation) and, to a lesser extent, via CYP2E1 to a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Ganciclovir is not significantly metabolized; it is primarily excreted unchanged by the kidneys via glomerular filtration and active tubular secretion. Less than 1% is metabolized to 9-[(1,3-dihydroxy-2-propoxymethyl)guanine].
Oxycodone is primarily metabolized in the liver via CYP3A4 to noroxycodone and via CYP2D6 to oxymorphone. Renal excretion accounts for approximately 87% of the administered dose, with 8.1% as unchanged oxycodone, 22.8% as noroxycodone, 9.1% as noroxymorphone, 3.2% as oxymorphone, and others. Fecal excretion is about 10%.
Renal excretion: >90% unchanged; biliary/fecal: minimal (<5%)
Approximately 45% bound to plasma proteins, primarily albumin.
1-2% bound; primarily to albumin (low binding)
Volume of distribution is 2.6-3.6 L/kg. This indicates extensive tissue distribution, with oxycodone widely distributed throughout body fluids and tissues, including the brain.
0.47-0.74 L/kg; indicates extensive distribution into tissues including brain, eye, and lungs
Oral immediate-release: 60-87% due to first-pass metabolism. Extended-release: approximately the same as immediate-release when adjusted for dose. Intravenous: 100%. Rectal: similar to oral (60-87%).
Oral: 6-9% (fasting); increased to 30% with food due to enhanced absorption
For Cr Cl 30-50 m L/min: administer every 6 hours; Cr Cl 10-29 m L/min: administer every 8 hours; Cr Cl < 10 m L/min: not recommended due to risk of oxycodone accumulation.
Cr Cl ≥70 m L/min: 5 mg/kg q12h (induction), 5 mg/kg q24h (maintenance); Cr Cl 50-69: 2.5 mg/kg q12h, then 2.5 mg/kg q24h; Cr Cl 25-49: 2.5 mg/kg q24h, then 1.25 mg/kg q24h; Cr Cl 10-24: 1.25 mg/kg q24h, then 0.625 mg/kg q24h; Cr Cl <10: 1.25 mg/kg 3 times/week after hemodialysis. Oral: Cr Cl ≥70: 1000 mg tid; 50-69: 1500 mg qd or 500 mg tid; 25-49: 1000 mg qd or 500 mg bid; 10-24: 500 mg qd; <10: 500 mg 3 times/week after dialysis.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend dosing interval; Child-Pugh C: contraindicated or use with extreme caution, maximum 50% of normal dose.
No dose adjustment required for hepatic impairment. Use with caution in severe hepatic dysfunction due to limited data.
Not recommended for children under 18 years due to risk of respiratory depression; for older adolescents (≥18 years), adult dosing may be considered.
Induction: 5 mg/kg IV every 12 hours for 14-21 days. Maintenance: 5 mg/kg IV every 24 hours. Oral dosing in children ≥9 years: 1000 mg three times daily with food; for children <9 years, use weight-based: 30 mg/kg per dose (max 1000 mg) three times daily.
Initiate at lowest effective dose, typically one-half of adult dose (one tablet every 6 hours) and titrate slowly; caution due to increased sensitivity and risk of falls and respiratory depression.
No specific dose adjustments beyond renal function. Closely monitor renal function and adjust dose based on Cr Cl.
Addiction, Abuse, and Misuse: Oxycodone exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk before prescribing, and monitor regularly for development of these behaviors or conditions. Life-Threatening Respiratory Depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially upon initiation or following a dose increase. Accidental Ingestion: Accidental ingestion of even one dose of oxycodone, especially by children, can result in a fatal overdose of oxycodone. Neonatal Opioid Withdrawal Syndrome: Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants: Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants may result in profound sedation, respiratory depression, coma, and death. Reserve for use in patients for whom alternative treatment options are inadequate. Hepatotoxicity: Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses exceeding 4000 mg per day, and often involve more than one acetaminophen-containing product.
Ganciclovir is associated with granulocytopenia, anemia, and thrombocytopenia. Animal studies have shown that ganciclovir is carcinogenic, mutagenic, and causes impairment of fertility and teratogenicity. It is indicated only for the treatment of CMV retinitis and prevention of CMV disease in transplant recipients. Not approved for congenital or neonatal CMV disease.
Risk of addiction, abuse, and misuse,Life-threatening respiratory depression,Accidental ingestion (especially in children),Neonatal opioid withdrawal syndrome,Risks from concomitant use with benzodiazepines or other CNS depressants,Hepatotoxicity from acetaminophen,Severe hypotension,Gastrointestinal effects (e.g., constipation, ileus),Seizures in patients with seizure disorders,Serotonin syndrome with concomitant serotonergic drugs,Adrenal insufficiency,Use in patients with head injury or increased intracranial pressure,Use in patients with acute abdominal conditions
Hematologic toxicity: Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, and bone marrow suppression, especially in patients with pre-existing cytopenias or on concomitant myelosuppressive drugs.,Renal impairment: Dose adjustment required; increased risk of toxicity in renal dysfunction.,Carcinogenicity and mutagenicity: Anticipated in humans based on animal data.,Teratogenicity: Embryotoxic and teratogenic in animals; use only if benefit outweighs risk.,Interaction with mycophenolate mofetil: May increase risk of hematologic toxicity.,Electrolyte disturbances: May cause hypocalcemia, hypokalemia, hyponatremia.,Ocular effects: Retinal detachment in patients with CMV retinitis (not directly drug-related).,Seizures and neurotoxicity: Rare, especially in patients with CNS conditions or renal impairment.
Hypersensitivity to oxycodone or acetaminophen,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment,Paralytic ileus,Severe hepatic impairment (for acetaminophen component),Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy
Hypersensitivity to ganciclovir, valganciclovir, or any component of the formulation.,Absolute neutrophil count < 500 cells/μL, platelet count < 25,000/μL, or hemoglobin < 8 g/d L (relative contraindication due to risk of worsening cytopenias).,Pregnancy (avoid unless potential benefit outweighs risk; embryotoxic in animals).
Avoid alcohol. Grapefruit juice may increase oxycodone levels (monitor for opioid effects); high-fat meals may delay absorption but not total exposure. No other significant dietary restrictions.
Take ganciclovir with food to reduce gastrointestinal upset. Avoid grapefruit juice as it may increase drug levels (weak interaction). No specific food restrictions otherwise.
Oxycodone/paracetamol (OXYCET). Oxycodone: FDA Category B (but Category D if prolonged use or near term). First trimester: Increased risk of neural tube defects, congenital heart defects; limited data, but avoid if possible. Second and third trimesters: Prolonged use may cause fetal dependence, withdrawal syndrome; near term, neonatal respiratory depression. Paracetamol: Category B; appears safe in standard doses but overdose causes fetal hepatotoxicity.
FDA Pregnancy Category B. Animal studies show teratogenicity (e.g., cleft palate, anophthalmia) at doses near human exposure. Human data limited; avoid first trimester unless benefit outweighs risk. Second/third trimester: potential for bone marrow suppression and nephrotoxicity in fetus; use only if clearly needed.
Oxycodone is excreted into breast milk; relative infant dose approximately 1.6-3.5% of maternal weight-adjusted dose. M/P ratio not firmly established. Use caution; monitor infant for sedation, respiratory depression, poor feeding. Paracetamol is safe; excreted in low levels. If prolonged maternal oxycodone use, risk of neonatal withdrawal.
Not recommended. M/P ratio unknown; ganciclovir is excreted into breast milk in rats. Potential for severe adverse effects in nursing infant (e.g., bone marrow suppression, carcinogenesis).
Oxycodone distribution volume increases in pregnancy; clearance may increase, potentially requiring higher doses to achieve analgesic efficacy, but no standard adjustment. Avoid chronic use; use lowest effective dose shortest duration. Paracetamol dose 650-1000 mg every 4-6 hours; max 4000 mg/day; no pregnancy-specific dose adjustment unless hepatic impairment.
No specific pregnancy dosing adjustments established. Pharmacokinetics may be altered due to increased plasma volume and renal clearance; monitor drug levels if available. Standard dosing: 5 mg/kg IV q12h x 14-21 days (induction), then 5 mg/kg/day (maintenance). Adjust for renal function (Cr Cl). Use lowest effective dose.
Oxycet is a combination of oxycodone and acetaminophen. Maximum acetaminophen daily dose is 4 g; in chronic alcohol use or hepatic impairment, limit to 2 g. Use with caution in elderly, respiratory compromise, or history of substance abuse. Constipation prophylaxis (e.g., stool softener) is recommended. Avoid concurrent use with other CNS depressants. Monitor for signs of tolerance, dependence, and misuse.
Monitor renal function closely; dose adjustment required in renal impairment. Ganciclovir is myelosuppressive; check CBC frequently, especially in patients with neutropenia. Use with caution in patients with pre-existing cytopenias. Administer IV infusion over at least 1 hour to reduce renal toxicity. Valganciclovir, the prodrug, is only for CMV retinitis in immunocompromised patients. Always maintain adequate hydration to prevent crystalluria.
Take this medication exactly as prescribed. Do not increase dose or frequency without consulting your doctor.,Do not combine with other products containing acetaminophen (e.g., Tylenol) to avoid exceeding 4000 mg per day.,Avoid alcohol while taking this medication; it increases the risk of liver damage and sedation.,This drug can cause drowsiness or dizziness; do not drive or operate heavy machinery until you know how it affects you.,Constipation is common; increase fluid and fiber intake, and consider using a stool softener as recommended.,Do not stop taking suddenly; your doctor will guide you on tapering to prevent withdrawal symptoms.,Store securely out of reach of others; unused medication should be disposed of properly.
Take this medication exactly as prescribed; do not skip doses or stop without consulting your doctor.,Ganciclovir may lower your blood cell counts, increasing risk of infection, bleeding, or anemia. Report any signs of infection (fever, chills), unusual bruising/bleeding, or fatigue immediately.,Keep all appointments for blood tests and kidney function monitoring.,Drink plenty of fluids to prevent kidney problems.,Use effective contraception during treatment and for at least 30 days after stopping for females, and for 90 days for males; ganciclovir can harm an unborn baby.,Do not breastfeed during treatment due to potential harm to the infant.,Avoid driving or operating machinery if you experience dizziness, confusion, or seizures.
No interactions on record
"Probenecid inhibits renal tubular secretion of ganciclovir, reducing its clearance and increasing its plasma concentration. This can potentiate the antiviral effect but also elevates the risk of dose-dependent adverse effects such as myelosuppression and nephrotoxicity. Concurrent use may require dose adjustment of ganciclovir and monitoring for toxicity."
"Combined use of ganciclovir and zidovudine results in additive myelosuppression, particularly neutropenia and anemia, due to overlapping bone marrow toxicity. This interaction increases the risk of severe hematologic adverse effects, including life-threatening infections and transfusion-dependent anemia. Patients with pre-existing cytopenias or those receiving other myelotoxic agents are at heightened risk."
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Zalcitabine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCET vs GANCICLOVIR, answered by our medical review team.
OXYCET is a Opioid Analgesic Combination that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, though it can interact with other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Acetaminophen is believed to produce analgesia through central action, possibly mediated through inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways, though the exact mechanism is not fully understood.. GANCICLOVIR is a Antiviral that works by Ganciclovir is a synthetic guanine nucleoside analog that inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and by incorporating into viral DNA, causing chain termination. It requires initial phosphorylation by viral thymidine kinase (CMV) or protein kinase (HSV).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCET and GANCICLOVIR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCET is: 1 tablet (325 mg acetaminophen and 5 mg oxycodone) orally every 4 to 6 hours as needed for pain; maximum 12 tablets per day.. The standard adult dose of GANCICLOVIR is: Induction: 5 mg/kg IV every 12 hours for 14-21 days. Maintenance: 5 mg/kg IV every 24 hours. Oral: 1000 mg three times daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCET and GANCICLOVIR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCET is classified as Category C. Oxycodone/paracetamol (OXYCET). Oxycodone: FDA Category B (but Category D if prolonged use or near term). First trimester: Increased risk of neural tube defects, congenital heart d. GANCICLOVIR is classified as Category D/X. FDA Pregnancy Category B. Animal studies show teratogenicity (e.g., cleft palate, anophthalmia) at doses near human exposure. Human data limited; avoid first trimester unless benef. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.